Classify the drugs for epilepsy
Reading File
Now let me search the medical library for antiepileptic drug classification.
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Excellent - found great sources. Let me read the most comprehensive ones in parallel.
Reading File
Reading File
Finding Sources
I found the drug table in Adams & Victor. Let me read the full table plus Katzung's pharmacology section.
Reading File
Reading File
Reading File
Finding Sources
I now have comprehensive data from Adams & Victor's and Katzung's. Let me also get the Goodman & Gilman's classification view.
Finding Sources
I have enough data from the textbooks. Let me now compile a comprehensive classification.# Classification of Drugs for Epilepsy (Antiepileptic Drugs / AEDs)
Antiepileptic drugs (AEDs) can be classified in several complementary ways: by generation, by mechanism of action, and by seizure type/indication. All three frameworks are used clinically.
1. Classification by Generation
First-Generation (Older / Classic) AEDs
| Drug | Key Feature |
|---|---|
| Phenobarbital | Oldest AED; GABA-A potentiation |
| Phenytoin | Narrow therapeutic index; nonlinear kinetics |
| Carbamazepine | Drug of choice for focal seizures |
| Ethosuximide | Drug of choice for pure absence seizures |
| Valproic acid (Valproate) | Broadest spectrum; drug of choice for juvenile myoclonic epilepsy |
| Primidone | Metabolized to phenobarbital |
| Clonazepam | Benzodiazepine; mainly adjunctive |
Second-Generation (Newer) AEDs
| Drug | Key Feature |
|---|---|
| Lamotrigine | Broad-spectrum; well tolerated; risk of SJS rash |
| Levetiracetam | Unique SV2A mechanism; minimal drug interactions |
| Topiramate | Broad-spectrum; weight loss; cognitive dulling |
| Gabapentin | Adjunctive for focal seizures; also used for neuropathic pain |
| Pregabalin | Similar to gabapentin; weight gain |
| Oxcarbazepine | Safer alternative to carbamazepine |
| Vigabatrin | Irreversible GABA-T inhibitor; used for infantile spasms |
| Tiagabine | GABA reuptake inhibitor |
| Zonisamide | Broad-spectrum; sulfonamide derivative |
| Felbamate | Broad-spectrum but hepatotoxic/aplastic anemia risk |
Third-Generation (Newest) AEDs
| Drug | Key Feature |
|---|---|
| Lacosamide | Slow inactivation of sodium channels; adjunctive focal seizures |
| Perampanel | AMPA glutamate receptor antagonist |
| Brivaracetam | SV2A modulator (like levetiracetam, less mood side effects) |
| Eslicarbazepine | Active metabolite of oxcarbazepine |
| Cenobamate | Dual mechanism; high seizure-free rates in focal seizures |
2. Classification by Mechanism of Action
Sodium Channel Blockers (reduce membrane excitability)
- Phenytoin, Carbamazepine, Oxcarbazepine, Eslicarbazepine, Lamotrigine, Zonisamide, Lacosamide
GABA Potentiators (enhance inhibitory neurotransmission)
| Subtype | Drugs |
|---|---|
| GABA-A receptor (allosteric) | Benzodiazepines (diazepam, lorazepam, clonazepam), Barbiturates (phenobarbital) |
| GABA synthesis increase | Valproate (indirect) |
| GABA-transaminase inhibitor (irreversible) | Vigabatrin |
| GABA reuptake inhibitor | Tiagabine |
T-type Calcium Channel Blockers (suppress thalamo-cortical rhythms - key for absence seizures)
- Ethosuximide, Valproate, Zonisamide
SV2A (Synaptic Vesicle Protein) Modulators (reduce neurotransmitter release)
- Levetiracetam, Brivaracetam
Glutamate (Excitatory) Antagonists
| Target | Drug |
|---|---|
| AMPA receptor | Perampanel, Topiramate (partial) |
| NMDA receptor | Valproate (partial) |
Potassium Channel Openers
- Retigabine/Ezogabine (KCNQ2-5 opener; largely discontinued due to pigmentation side effects)
Multiple / Mixed Mechanisms
| Drug | Mechanisms |
|---|---|
| Valproate | Na⁺ channel block + T-Ca²⁺ block + GABA potentiation + NMDA inhibition |
| Topiramate | Na⁺ channel + AMPA block + GABA potentiation + Ca²⁺ channel block + carbonic anhydrase inhibition |
3. Classification by Seizure Type / Indication
Focal (Partial) Seizures - Drugs of Choice
- Carbamazepine, Oxcarbazepine (first-line)
- Lamotrigine, Levetiracetam, Lacosamide (alternatives/adjuncts)
- Phenytoin, Phenobarbital, Valproate (effective but older)
Generalized Tonic-Clonic Seizures (GTCS)
- Valproate (first-line, especially if absence co-exists)
- Lamotrigine, Levetiracetam, Topiramate
- Phenytoin, Carbamazepine (effective but not for other generalized types)
Absence Seizures
- Ethosuximide - drug of choice for pure absence
- Valproate - drug of choice if absence + GTCS co-exist
- Lamotrigine (less effective, but used in females of childbearing age)
- Avoid: Carbamazepine, Phenytoin, Gabapentin, Vigabatrin (may worsen absence)
Juvenile Myoclonic Epilepsy (JME)
- Valproate - first-line
- Levetiracetam, Lamotrigine, Topiramate (alternatives)
- Lifelong treatment usually required
Infantile Spasms (West Syndrome)
- Vigabatrin (especially tuberous sclerosis)
- ACTH (corticotropin) - first-line hormonal therapy
- Pyridoxine in pyridoxine-dependent cases
Lennox-Gastaut Syndrome
- Valproate, Lamotrigine (drug of choice for drop attacks), Topiramate
- Clobazam, Rufinamide, Felbamate (adjunctive)
- Cannabidiol (Epidiolex)
Status Epilepticus (Acute)
- Lorazepam IV (first-line)
- Diazepam IV / rectal
- Phenytoin / Fosphenytoin IV (second-line)
- Valproate IV, Levetiracetam IV, Phenobarbital IV
- Midazolam IM (when IV access unavailable)
4. Summary Table of Key Drugs
| Drug | Generation | Mechanism | Best For | Key Adverse Effect |
|---|---|---|---|---|
| Valproate | 1st | Multiple | Broad-spectrum (JME, GTCS, absence) | Teratogenicity, hepatotoxicity, weight gain |
| Phenytoin | 1st | Na⁺ channel | Focal, GTCS | Nonlinear kinetics, gingival hyperplasia, hirsutism |
| Carbamazepine | 1st | Na⁺ channel | Focal seizures | Hyponatremia, skin rash (SJS in HLA-B*1502) |
| Ethosuximide | 1st | T-Ca²⁺ channel | Absence seizures | GI upset, headache |
| Phenobarbital | 1st | GABA-A | Focal, GTCS | Sedation, cognitive impairment |
| Lamotrigine | 2nd | Na⁺ channel | Broad-spectrum | SJS rash (slow titration required) |
| Levetiracetam | 2nd | SV2A | Broad-spectrum | Mood disturbance, irritability |
| Topiramate | 2nd | Multiple | Broad-spectrum | Cognitive dulling ("dopamax"), nephrolithiasis |
| Oxcarbazepine | 2nd | Na⁺ channel | Focal seizures | Hyponatremia |
| Vigabatrin | 2nd | GABA-T inhibitor | Infantile spasms | Irreversible visual field defects |
| Gabapentin | 2nd | Ca²⁺ channel (alpha-2-delta) | Focal (adjunct) | Sedation, weight gain |
| Lacosamide | 3rd | Na⁺ channel (slow inactivation) | Focal seizures | PR interval prolongation |
| Perampanel | 3rd | AMPA antagonist | Focal + GTCS (adjunct) | Dizziness, aggression |
| Brivaracetam | 3rd | SV2A | Focal seizures | Better tolerated than levetiracetam |
Sources:
- Adams and Victor's Principles of Neurology, 12th Ed., Table 15-5 (Antiepileptic Drugs - Mechanisms, Indications, Limitations)
- Katzung's Basic and Clinical Pharmacology, 16th Ed., Ch. 24 (Antiseizure Medications)
This is a shared conversation. Sign in to Orris to start your own chat.